BELLUS Health (TSE:BLU) Stock Price Down 1.3%

BELLUS Health Inc (TSE:BLU) was down 1.3% on Wednesday . The company traded as low as C$8.74 and last traded at C$9.10, approximately 40,150 shares changed hands during mid-day trading. A decline of 35% from the average daily volume of 62,139 shares. The stock had previously closed at C$9.22.

The company has a debt-to-equity ratio of 0.15, a current ratio of 14.10 and a quick ratio of 13.97. The company has a fifty day moving average of C$8.94 and a 200-day moving average of C$5.96. The firm has a market capitalization of $510.59 million and a PE ratio of -16.08.

BELLUS Health Company Profile (TSE:BLU)

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

See Also: What does an outperform rating mean?

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit